|
|
Sanofi and its Subsidiary Genzyme to Feature More than 20 Data Presentations |
 Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that more than 20 data presentations from the company's growing multiple sclerosis (MS) portfolio will be showcased at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS 2011). Data to be presented will include new results from pivotal Phase III clinical trials of the company's lead investigational candidates for the treatment of relapsing MS, LemtradaTM (alemtuzumab) and AubagioTM (oral teriflunomide), and will be featured in platform and poster presentations. |
|
|
|
|
Thursday, 16 February 2012 |
 |
 |
 |
|
|
'Epilepsy In Our Time' |
 'Epilepsy In Our Time', a video diary, explores life with epilepsy from the perspective of those living with the condition on European Epilepsy Day - 13th February 2012. The disease is the most common serious brain disorder worldwide, affecting 6 million people in Europe(1). European Epilepsy Day is an initiative of the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) and this year's theme is the burden of epilepsy. |
|
|
|
|
BYETTA® approved for use with basal insulin in Europe |
 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced that the European Commission has granted marketing authorization to BYETTA® (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. |
|
|
|
|
|
Shire receives prestigious EURORDIS Company Award for exemplary work in rare diseases |
 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has received the prestigious Company Award from the European Organisation for Rare Diseases (EURORDIS) for its exemplary work in the field of rare diseases. The EURORDIS Company Award, presented last night at the First International Rare Disease Day Gala Dinner in Brussels, is designed to reward outstanding accomplishments of pioneering companies developing treatments for rare disease. |
|
|
|
|
Lundbeck disagrees with the Statement of Objections issued by the European Commission |
 H. Lundbeck A/S (Lundbeck) announces that the European Commission has issued a Statement of Objections to Lundbeck. The Statement of Objections is regarding agreements concluded with four generic competitors concerning citalopram. A Statement of Objections does not represent the European Commission's final decision. Any final decision by the Commission is appealable to the European Courts (General Court and then the European Court of Justice). The whole process could take several years to reach a conclusion. |
|
|
|
|
|
|
|
|
Page 7 of 254 |
